 |
Herestraat 49 B-912
3000 Leuven |
phone: +32 16 34 57 83
fax: +32 16 34 59 90 |
Curriculum Vitae
1971 to 1975
|
B.A.Sc., University of Toronto, Canada |
| 1975 to 1979 |
M.D., University of Toronto, Canada |
| 1979 to 1983 |
FRCP(C), University of Toronto, Canada |
| 1983 to 1988 |
FACP, Diploma in Hematology-Oncology, Harvard University, Boston, MA |
| 2000 to 2004 |
M.B.A., Heriot Watt University of Edinburgh, Scotland |
| 2006 |
Ph.D. in Medical Sciences, University of Leuven |
Research
| The goal of my research is to delineate the multiple protective mechanisms of the vascular endothelium, to explore how these are integrated under different stress conditions and in different organs, to translate these insights into the development of innovative therapeutic approaches and to gain genetic insights to explain human disease. Three major research programs are currently ongoing in my group.
Thrombomodulin, a vascular endothelial sentry
Thrombomodulin (TM) is a pan-endothelial transmembrane glycoprotein which critically regulates coagulation. We are identifying novel molecular pathways by which TM modulates innate immunity, inflammation and tumorigenesis using biochemical approaches, mouse models and human genetic studies.
The perplexing story of the “tumor endothelial marker”, endosialin
Endosialin (cd248) w as initially identified as a tumor endothelial marker, but is now recognized to be expressed by pericytes. Endosialin has striking structural similarities to TM and we are examining its structure-function correlates in transgenic mouse models, having determined that distinct domains modulate inflammation and tumorigenesis.
Survivin, a cell-survival molecule
Survivin is the smallest IAP family member, and is unique, in that it inhibits apoptosis, regulates cytokinesis, and promotes the cell cycle. Using transgenic mice, we are assessing its role in neurovascular disease, acute renal failure, and as a therapeutic target for several diseases. |
 |
Publications
Staff
|
